litlas
ログインアカウント作成

Semiglazov Vf

1992–2025 年に発表

59
論文数
30,761
被引用数
51
h 指数
59
i10 指数

被引用数

Semiglazov Vf の年別被引用数1981 年: 被引用 1 件1996 年: 被引用 1 件1997 年: 被引用 1 件1998 年: 被引用 2 件1999 年: 被引用 6 件2000 年: 被引用 2 件2001 年: 被引用 7 件2002 年: 被引用 9 件2003 年: 被引用 14 件2004 年: 被引用 11 件2005 年: 被引用 9 件2006 年: 被引用 41 件2007 年: 被引用 70 件2008 年: 被引用 76 件2009 年: 被引用 55 件2010 年: 被引用 107 件2011 年: 被引用 105 件2012 年: 被引用 139 件2013 年: 被引用 216 件2014 年: 被引用 287 件2015 年: 被引用 303 件2016 年: 被引用 334 件2017 年: 被引用 320 件2018 年: 被引用 282 件2019 年: 被引用 1,001 件2020 年: 被引用 1,123 件2021 年: 被引用 1,137 件2022 年: 被引用 921 件2023 年: 被引用 655 件2024 年: 被引用 957 件2025 年: 被引用 443 件2026 年: 被引用 13 件1982〜1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,296 件、この内訳の 19.8%中国: 引用元論文 1,295 件、この内訳の 11.1%イタリア: 引用元論文 806 件、この内訳の 6.9%ドイツ: 引用元論文 635 件、この内訳の 5.5%イギリス: 引用元論文 628 件、この内訳の 5.4%スペイン: 引用元論文 473 件、この内訳の 4.1%フランス: 引用元論文 467 件、この内訳の 4%スイス: 引用元論文 405 件、この内訳の 3.5%ベルギー: 引用元論文 346 件、この内訳の 3%カナダ: 引用元論文 334 件、この内訳の 2.9%日本: 引用元論文 286 件、この内訳の 2.5%オランダ: 引用元論文 276 件、この内訳の 2.4%
0%19.8%その他 28.9%

機関

分野

  • Medicine51.7%
  • Biochemistry, Genetics and Molecular Biology40.3%
  • Immunology and Microbiology2.2%
  • Computer Science1.8%
  • Materials Science1%
  • Engineering0.9%
  • その他2.1%

トピック

  • Breast Cancer Treatment Studies14.2%
  • HER2/EGFR in Cancer Research8.7%
  • Breast Lesions and Carcinomas4.9%
  • Advanced Breast Cancer Therapies4.5%
  • Cancer Immunotherapy and Biomarkers3.9%
  • Cancer Treatment and Pharmacology3.4%
  • その他60.4%

共著者

全論文

検索で開く
  1. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    著者: Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M. Swain, Tatiana M. Prowell, Sibylle Loibl, D. Lawrence Wickerham, Jan Bogaerts, José Baselga, Charles M. Perou, Gideon M. Blumenthal, Jens‐Uwe Blohmer, Eleftherios P. Mamounas, Jonas Bergh, Semiglazov Vf, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A. Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz - The Lancet 2014 被引用: 4,710

  2. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    著者: Aron Goldhirsch, Eric P. Winer, Alan S. Coates, Richard D. Gelber, Martine Piccart, Beat Thürlimann, Hans-Jörg Senn, Kathy S. Albain, Fabrice André, Jonas Bergh, Hervé Bonnefoi, Denisse Bretel-Morales, Harold J. Burstein, Fátima Cardoso, Monica Castiglione‐Gertsch, Alan S. Coates, Marco Colleoni, Alberto Costa, Giuseppe Curigliano, Nancy E. Davidson, Angelo Di Leo, Bent Ejlertsen, John Forbes, Richard D. Gelber, Michael Gnant, Aron Goldhirsch, Pamela J. Goodwin, Paul E. Goss, Jay R. Harris, Daniel F. Hayes, Clifford A. Hudis, James N. Ingle, Jacek Jassem, Zefei Jiang, Per Karlsson, Sibylle Loibl, Monica Morrow, Moïse Namer, C. Kent Osborne, Ann H. Partridge, Frédérique Penault‐Llorca, Charles M. Perou, Martine Piccart, Kathleen I. Pritchard, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Beat Thürlimann, Masakazu Toi, Andrew Tutt, Michael Untch, Giuseppe Viale, Toru Watanabe, Nicholas Wilcken, Eric P. Winer, William C. Wood - Annals of Oncology 2013 被引用: 3,715

  3. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    著者: Sandra M. Swain, David Miles, Sung‐Bae Kim, Young‐Hyuck Im, Seock‐Ah Im, Semiglazov Vf, Eva Ciruelos, Andreas Schneeweiß, Sherene Loi, Estefanía Monturus, Emma Clark, Adam Knott, Eleonora Restuccia, Mark Benyunes, Javier Cortés, Richy Agajanian, Rizvana Ahmad, Bahriye Aktas, Victor Hugo Medeiros Alencar, Dino Amadori, Jurandyr Moreira de Andrade, Fábio Franke, Catia Angiolini, Kenjiro Aogi, Jess F. Armor, Wichit Arpornwirat, L. Assersohn, William Audeh, Walter E. Aulitzky, Sérgio Jobim Azevedo, Maria Alejandra Bartoli, Norberto Batista López, María Inés Bianconi, Laura Biganzoli, Ruemu Birhiray, Marianna Bitiņa, Ron Blachy, Kimberly Blackwell, Rita A. Blanchard, Paulette Blanchet, Ion Boiangiu, B. Bower, Christine Brezden‐Masley, Adam Brufsky, Leanne S. Budde, Priscilla B. Caguioa, Lourdes Calvo, Mario Campone, Robert R. Carroll, Hugo R. Castro, Valorie F. Chan, Veena Charu, Saverio Cinieri, Michael Clemens, Emilio Alba Conejo, Eduardo Côrtes, Bruno Coudert, Eduardo Cronemberger, Daniel de Iracema Gomes Cubero, Shaker R. Dakhil, Brooke Daniel, Neville Davidson, Maria de Fátima Dias Gauí, Susana de la Cruz, María del Pilar, G. Delgado, John Ellerton, César Estuardo, Louis Fehrenbacher, Jean-­Marc Ferrero, Patrick J. Flynn, Małgorzata Foszczyńska‐Kłoda, Sandra Franco, Hirofumi Fujii, Chris Gallagher, Teresa Gamucci, N Giacomi, Miguel Gil Gil, Antonio González-Martı́n, Vera Gorbunova, E. Gotovkin, Nathan Green, Elza Grincuka, Eva‐Maria Grischke, Vincent Hansen, Jeffrey B. Hargis, Maik Hauschild, Roberto Hegg, Carolyn B. Hendricks, Róbert Hermann, Paulo M. Hoff, Jun Horiguchi, Javier Hornedo Muguiro, Stefano Iacobelli, Kenichi Inoue, Gustavo Ismael, Yoshinori Itoh, Dr Hiroji Iwata, D Jendiroba, Rosa Jochim ほか 122 名 - The Lancet Oncology 2020 被引用: 898

  4. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

    著者: Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im, Laslo Roman, Ling‐Ming Tseng, Mei-Ching Liu, Aňa Lluch, Elżbieta Starosławska, Juan de la Haba-Rodríguez, Seock‐Ah Im, José Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Semiglazov Vf, Vichien Srimuninnimit, Giulia Bianchi, Tania Szado, Jayantha Ratnayake, Graham Ross, Pinuccia Valagussa - The Lancet Oncology 2011 被引用: 2,358

  5. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

    著者: David Miles, Joseph Gligorov, Fabrice André, David Cameron, Andreas Schneeweiß, Carlos H. Barrios, Binghe Xu, Andrew Wardley, Diego Kaen, Livia Andrade, Semiglazov Vf, Mattea Reinisch, Shilpen Patel, Monika Patre, L. Morales, Sipahee Lal Patel, Manika Kaul, Teresa Barata, Joyce O’Shaughnessy, Q. Zhang, Binghe Xu, Zhimin Shao, Xiangyu Wang, Cuizhi Geng, Xingchen Yan, Zhongsheng Tong, Kunwei Shen, Yongmei Yin, Tao Sun, James Chih‐Hsin Yang, J Feng, Min Yan, Yan Wang, Qiang Liu, S. Zhang, Michelino De Laurentiis, Armando Santoro, Valentina Guarneri, Marco Colleoni, Clara Natoli, Laura Cortesi, Sabino De Placido, Lorenzo Gianni, Francesco Ferraù, Lorenzo Livi, Alberto Zambelli, Lucia Del Mastro, Giuseppe Tonini, Filippo Montemurro, Giulia Bianchi, R. Pedersini, Salvatore A. Del Prete, Giacomo Allegrini, Giuseppe Naso, Patrizia Vici, D. Loirat, Audrey Mailliez, Franck Priou, Olivier Trédan, F. Dalenc, Christophe Perrin, Joseph Gligorov, Morales-Pancorbo David, Nadine Dohollou, Luís Teixeira, Fabien Brocard, Antoine Arnaud, Suzette Delaloge, Jean‐Philippe Spano, Luigi Mansi, Livia Andrade, Fernanda Damian, José Luiz Pedrini, Sandra M. Aleixo, Roberto Hegg, R. Junior, Mattea Reinisch, Marcus Schmidt, C. Wenzel, E.‐M. Grischke, Andreas Schneeweiß, Marianne Just, Nadia Harbeck, Claudia Schumacher, Ubong Peters, Dorothea Fischer, Helmut Forstbauer, Rüdiger Liersch, Ellen Warner, Nathaniel Bouganim, C. T. Doyle, Julie Price Hiller, Ted Vandenberg, Michel Pavic, Andrew Robinson, Gloria Roldan Urgoiti, Nadia Califaretti, Ahmet Alacacıoğlu, M. Gumus, Bülent Yalçın ほか 68 名 - Annals of Oncology 2021 被引用: 729

  6. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

    著者: Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, C. Zamagni, Marc Thill, A. Antón, Stefania Zambelli, Giampaolo Bianchini, Salvatore Russo, Eva Ciruelos, Richard Greil, Semiglazov Vf, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, I. Maffeis, Pinuccia Valagussa, Giuseppe Viale - Annals of Oncology 2022 被引用: 386

  7. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

    著者: Alan S. Coates, Eric P. Winer, Aron Goldhirsch, Richard D. Gelber, Michael Gnant, Martine Piccart, Beat Thürlimann, H.-J. Senn, Fabrice André, José Baselga, Jonas Bergh, Hervé Bonnefoi, Harold J. Burstein, Fátima Cardoso, Monica Castiglione‐Gertsch, Alan S. Coates, Marco Colleoni, Giuseppe Curigliano, Nancy E. Davidson, Angelo Di Leo, Bent Ejlertsen, John Forbes, Viviana Galimberti, Richard D. Gelber, Michael Gnant, Aron Goldhirsch, Pamela J. Goodwin, Nadia Harbeck, Daniel F. Hayes, Jens Huober, Clifford A. Hudis, James N. Ingle, Jacek Jassem, Zefei Jiang, Per Karlsson, Monica Morrow, Roberto Orecchia, C. Kent Osborne, Ann H. Partridge, Lorena de la Peña, Martine Piccart, Kathleen I. Pritchard, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Beat Thürlimann, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Gϋnter von Minckwitz, Toru Watanabe, Timothy J. Whelan, Eric P. Winer, Binghe Xu - Annals of Oncology 2015 被引用: 1,837

  8. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

    著者: Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im, Ling‐Ming Tseng, Mei-Ching Liu, Aňa Lluch, Elżbieta Starosławska, Juan de la Haba-Rodríguez, Seock‐Ah Im, José Luiz Pedrini, Brigitte Poirier, Paolo Morandi, Semiglazov Vf, Vichien Srimuninnimit, Giulia Bianchi, Domenico Magazzù, Virginia McNally, Hannah Douthwaite, Graham Ross, Pinuccia Valagussa - The Lancet Oncology 2016 被引用: 874

  9. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    著者: Giuseppe Curigliano, Harold J. Burstein, Eric P. Winer, Michael Gnant, Peter Dubsky, Sibylle Loibl, Marco Colleoni, Meredith M. Regan, Martine Piccart, Hans-Jörg Senn, Beat Thürlimann, Fabrice André, José Baselga, Jonas Bergh, Hervé Bonnefoi, Sara Y. Brucker, Fátima Cardoso, Lisa A. Carey, Eva Ciruelos, Jack Cuzick, Carsten Denkert, Angelo Di Leo, Bent Ejlertsen, Prudence A. Francis, V.E. Galimberti, Judy E. Garber, Bahadır M. Güllüoğlu, Pamela J. Goodwin, Nadia Harbeck, Daniel F. Hayes, Chiun‐Sheng Huang, Jens Huober, Hussein Khaled, Jacek Jassem, Zefei Jiang, Per Karlsson, Monica Morrow, Roberto Orecchia, Kent C. Osborne, Olivia Pagani, Ann H. Partridge, K. Pritchard, Jungsil Ro, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Toru Watanabe, Timothy J. Whelan, Binghe Xu - Annals of Oncology 2017 被引用: 1,255

  10. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

    著者: José Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Evandro de Azambuja, Claudia Aura, Henry Gómez, Phuong Dinh, Karine Fauria, Veerle Van Dooren, Gursel Aktan, Aron Goldhirsch, Tsai-Wang Chang, Zsolt Horváth, M.A. Coccia-Portugal, Julien Dômont, Ling-Min Tseng, Georg Kunz, Joohyuk Sohn, Semiglazov Vf, Guillermo Lerzo, Markéta Palácová, Volodymyr Probachai, Lajos Pusztai, Michael Untch, Richard D. Gelber, Martine Piccart - The Lancet 2012 被引用: 1,314

  11. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

    著者: Luca Gianni, W. Eiermann, Semiglazov Vf, Alexey Manikhas, Aňa Lluch, S. Tjulandin, Milvia Zambetti, Federico Vázquez, Mikhail Byakhow, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Roberta Baronio, A. Feyereislova, Claire Barton, Pinuccia Valagussa, José Baselga - The Lancet 2010 被引用: 1,268

  12. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

    著者: Luca Gianni, W. Eiermann, Semiglazov Vf, Aňa Lluch, Sergei Tjulandin, Milvia Zambetti, Angela Moliterni, Federico Vázquez, M. Byakhov, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Domenico Magazzù, Dominik Heinzmann, Jutta Steinseifer, Pinuccia Valagussa, José Baselga - The Lancet Oncology 2014 被引用: 491

  13. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

    著者: Sandra M. Swain, Sung‐Bae Kim, Javier Cortés, Jungsil Ro, Semiglazov Vf, Mario Campone, Eva Ciruelos, Jean-­Marc Ferrero, Andreas Schneeweiß, Adam Knott, Emma Clark, Graham Ross, Mark Benyunes, José Baselga - The Lancet Oncology 2013 被引用: 1,000

  14. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

    著者: Xavier Pivot, Joseph Gligorov, Volkmar Müller, Peter Barrett‐Lee, Sunil Verma, Ann Knoop, Giuseppe Curigliano, Semiglazov Vf, Guillermo López-Vivanco, Valerie Jenkins, Nana Scotto, Stuart Osborne, Lesley Fallowfield - The Lancet Oncology 2013 被引用: 226

  15. Challenges to effective cancer control in China, India, and Russia

    著者: Paul E. Goss, Kathrin Strasser‐Weippl, Brittany Bychkovsky, Lei Fan, Junjie Li, Yanin Chávarri-Guerra, Pedro Emanuel Rubini Liedke, C.S. Pramesh, Tanja Badovinac-Črnjević, Yuri Sheikine, Chen Zhu, You‐Lin Qiao, Zhi‐Ming Shao, Yi‐Long Wu, Daiming Fan, Louis W.C. Chow, Jun Wang, Qiong Zhang, Shiying Yu, Gordon C Shen, Jie He, Arnie Purushotham, Richard Sullivan, Rajendra Badwe, Shripad Banavali, Reena Nair, Lalit Kumar, Purvish M. Parikh, Somasundarum Subramanian, Pankaj Chaturvedi, Subramania Iyer, Surendra S. Shastri, Raghunadharao Digumarti, Enrique Soto‐Pérez‐de‐Celis, Dauren Adilbay, Semiglazov Vf, С. В. Орлов, Dilyara Kaidarova, Ilya Tsimafeyeu, Sergei Tatishchev, Kirill D Danishevskiy, Marc Hurlbert, Caroline Vail, Jessica St. Louis, Arlene Chan - The Lancet Oncology 2014 被引用: 504

  16. Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

    著者: Aleix Prat, Giampaolo Bianchini, Marlène Thomas, Anton Belousov, Maggie C.U. Cheang, Astrid Koehler, Patricia Gómez, Semiglazov Vf, W. Eiermann, Sergei Tjulandin, Mikhail Byakhow, Begoña Bermejo, Milvia Zambetti, Federico Vázquez, Luca Gianni, José Baselga - Clinical Cancer Research 2014 被引用: 236

  17. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

    著者: W. Eiermann, Stefan Paepke, Justus Appfelstaedt, Antonio Llombart‐Cussac, J. Eremin, J. Vinholes, L. Mauriac, Matthew J. Ellis, M. Lassus, Hilary A. Chaudri‐Ross, Margaret Dugan, M. Borgs, Semiglazov Vf - Annals of Oncology 2001 被引用: 716

  18. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

    著者: Xavier Pivot, Alexey Manikhas, Zurawski Bogdan, Ewa Chmielowska, Bogusława Karaszewska, R. Allerton, Stephen Chan, Alessandra Fabi, Paolo Bidoli, Stefania Gori, Eva Ciruelos, Magdolna Dank, Lajos Hornyák, Sara Margolin, Arnd Nusch, Roma Parikh, Fareha Nagi, Michelle DeSilvio, Sergio Santillana, Ramona F. Swaby, Semiglazov Vf - Journal of Clinical Oncology 2015 被引用: 251

  19. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

    著者: Xavier Pivot, Joseph Gligorov, Volkmar Müller, Giuseppe Curigliano, Ann Knoop, Sunil Verma, Valerie Jenkins, Nana Scotto, Stuart Osborne, Lesley Fallowfield, Lesley Fallowfield, Valerie Jenkins, Justine Kilkerr, C. Langridge, Kathryn Monson, Erik Jakobsen, Mette Holck Nielsen, Soeren Linnet, Ann Knoop, Xavier Pivot, Hervé Bonnefoi, Mireille Mousseau, Laurent Zelek, Hugues Bourgeois, Claudia Lefeuvre, Thomas Bachelot, Thierry Petit, Étienne Brain, Christelle Lévy, Joseph Gligorov, Doris Augustin, Heiko Graf, Georg Heinrich, Hendrik Kroening, Sherko Küemmel, Volkmar Müller, Friedrich Overkamp, Tjoung‐Won Park‐Simon, Marcus Schmidt, Lidia Perlova-Griff, Christopher Wolf, Marco Colleoni, Alberto Ballestrero, Antônio Bernardo, Angela Stefania Ribecco, Luca Gianni, Giuseppe Curigliano, E. Brewczynska, Jacek Jassem, Vadim Shirinkin, Alexey Manikhas, В. В. Дворниченко, Mikhail Lichinitser, Semiglazov Vf, Guzel Mukhametshina, Irina Bulavina, Enrique Espinosa Arranz, Francisco Carabantes Ocón, Guillermo López-Vivanco, Javier Salvador Bofill, Ignacio Porras Quintela, Alfonso Sánchez Muñoz, Yolanda Fernández Pérez, Javier Cassinello Espinosa, Jose Alvarez, Rodrigo Lastra del Prado, LuisLa Cruz De Merino, José Manuel Pérez García, Santos Enrech Francés, Per Edlund, Bengt Norberg, Anna-Karin Wennstig, Pehr Lind, Nik Hauser, Christoph Tausch, Celalettin Camcı, Fikret Arpacı, Hüseyin Abalı, Rüçhan Uslu, Saad Tahir, Duncan Wheatley, Stephen Chan, Peter Barrett‐Lee, Karen McAdam, Richard Simcock, Russell Burcombe, Robert H. El-Maraghi, Nadia Califaretti, Silvana Spadafora, Sandeep Sehdev, Amer Sami, Sunil Verma - Annals of Oncology 2014 被引用: 176

  20. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2 -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial

    著者: Luca Gianni, Mauro Mansutti, Antonio Antón, Lourdes Calvo, Giancarlo Bisagni, Begoña Bermejo, Semiglazov Vf, Marc Thill, José Ignacio Chacón, Arlene Chan, Serafín Morales, Isabel Álvarez, Arrate Plazaola, Milvia Zambetti, Andrew Redfern, Christian Dittrich, Rebecca Dent, Domenico Magazzù, Raffaella De Fato, Pinuccia Valagussa, Ignacio Tusquets - JAMA Oncology 2018 被引用: 155

  21. Immunology and immunotherapy in breast cancer

    著者: Semiglazov Vf, A.I. Tseluiko Tseluiko, Asel Kudaybergenova, Anna Artemyeva, Petr Krivorotko, Roman Donskih - Cancer Biology and Medicine 2022 被引用: 36

  22. LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

    著者: Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Marc Thill, A. Antón Torres, Giampaolo Bianchini, E. Sevillano Fernandez, Stefania Russo, Eva Ciruelos, Richard Greil, Semiglazov Vf, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, Riccardo Spezia, Hoda Ali, Giuseppe Viale - Annals of Oncology 2023 被引用: 27

  23. Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

    著者: José Baselga, Semiglazov Vf, Peter van Dam, Alexey Manikhas, Meritxell Bellet, José Mayordomo, Mario Campone, E. Kubista, Richard Greil, Giulia Bianchi, Jutta Steinseifer, Betty Molloy, Erika Tokaji, Humphrey Gardner, Penny Phillips, Michael Stumm, Heidi A. Lane, J. Michael Dixon, W. Jonat, Hope S. Rugo - Journal of Clinical Oncology 2009 被引用: 658

  24. AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

    著者: Luca Gianni, Gilles Romieu, М. Р. Личиницер, Sérgio Serrano, Mauro Mansutti, Xavier Pivot, Paola Mariani, Fabrice André, Arlene Chan, Oleg Lipatov, Stephen Chan, Andrew Wardley, Richard Greil, N. Moore, Sylvie Prot, Céline Pallaud, Semiglazov Vf - Journal of Clinical Oncology 2013 被引用: 257